These data confirmed that the combination of tucatinib and T-DM1 impedes the growth of HER2-positive tumors through the suppression of HER2-mediated proliferative signaling and promotes the death of HER2-positive tumor cells. The gene discussed is ERBB2; the disease is neoplasm.